Skip to main content
SpringerLink
Log in

Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow

  • Original Article – Cancer Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The 7th Heidelberg Myeloma Workshop was held on April 5th and 6th, 2019 at the University Hospital Heidelberg.

Methods and results

Main topics of the meeting were (1) diagnostics and prognostic factors, (2) role of immunotherapy in multiple myeloma (MM), (3) current therapy of MM, (4) biology and genomics of MM as well as (5) novel treatment concepts. A debate on the status of minimal residual disease (MRD) driven therapy was held.

Conclusion

Diagnostics and treatment of newly diagnosed and relapsed MM are continuously evolving. While advances in the field of (single cell) genetic analysis now allow for characterization of the disease at an unprecedented resolution, immunotherapeutic approaches and MRD testing are at the forefront of the current clinical trial landscape.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Baertsch M-A, Schlenzka J, Christina H et al (2018) Subgroup analyses of the randomized GMMG phase III multicenter trial relapse suggest survival benefit of salvage autologous transplant primarily in low risk multiple myeloma. Blood 132(Suppl 1):254

    Article  Google Scholar 

  • Bailly C, Leforestier R, Jamet B et al (2017) PET imaging for initial staging and therapy assessment in multiple myeloma patients. Int J Mol Sci 18(2):445

    Article  CAS  PubMed Central  Google Scholar 

  • Cavo M, Gay FM, Patriarca F et al (2017) Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02/HO95 study. Blood 130(Suppl 1):401

    Google Scholar 

  • Cavo M, Goldschmidt H, Rosinol L et al (2018) Double vs single autologous stem cell transplantation for newly diagnosed multiple myeloma: long-term follow-up (10-years) analysis of randomized phase 3 studies. Blood 132(Suppl 1):124

    Article  Google Scholar 

  • Dimopoulos MA, Oriol A, Nahi H et al (2016a) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319–1331

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, Sonneveld P, Leung N et al (2016b) International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 34:1544–1557

    Article  PubMed  Google Scholar 

  • Dimopoulos MA, Dytfeld D, Grosicki S et al (2018a) Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 379(19):1811–1822

    Article  CAS  PubMed  Google Scholar 

  • Dimopoulos MA, San-Miguel J, Belch A et al (2018b) Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica 103(12):2088–2096

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dimopoulos MA, Mateos M-V, Cavo M et al (2018c) One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (Pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): Alcyon. Blood 132(Suppl 1):156

    Article  Google Scholar 

  • Dittrich T, Benner A, Kimmich C et al (2019) Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica 104(7):1451–1459

    Article  PubMed  PubMed Central  Google Scholar 

  • Facon T, Kumar SK, Plesner T et al (2018) Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA). Blood 132(Suppl 1): LBA-2

    Article  Google Scholar 

  • Gertz MA (2018) Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment. Am J Hematol 93(9):1169–1180

    Article  CAS  PubMed  Google Scholar 

  • Goldschmidt H, Mai EK, Dürig J et al (2017) Response-adapted lenalidomide maintenance in newly diagnosed, transplant-eligible multiple myeloma: results from the multicenter phase III GMMG-MM5 trial. Blood 130(Suppl 1):400

    Google Scholar 

  • Goldschmidt H, Baertsch M-A, Schlenzka J et al (2018) Salvage autologous transplant and lenalidomide maintenance versus continuous lenalidomide/dexamethasone for relapsed multiple myeloma: results of the randomized GMMG phase III multicenter trial relapse. Blood 132(Suppl 1):253

    Article  Google Scholar 

  • Guo G, Raje NS, Seifer C et al (2018) Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia 32(8):1838–1841

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hillengass J, Usmani S, Rajkumar SV et al (2019) International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 20(6):e302–e312

    Article  PubMed  Google Scholar 

  • Kumar S, Paiva B, Anderson KC et al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346

    Article  PubMed  Google Scholar 

  • Kumar SK, Callander NS, Alsina M et al (2018) NCCN guidelines insights: multiple myeloma, version 3.2018. J Natl Compr Cancer Netw 16(1):11–20

    Article  Google Scholar 

  • Lakshman A, Rajkumar SV, Buadi FK et al (2018) Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 8(6):59

    Article  PubMed  PubMed Central  Google Scholar 

  • Lohr JG, Kim S, Gould J et al (2016) Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med 8(363):363ra147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Manier S, Park J, Capelletti M et al (2018) Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun 9(1):1691

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mateos M-V, Dimopoulos MA, Cavo M et al (2017) Phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for transplant (ALCYONE). Blood 130(Suppl 1): LBA-4 (SH Late Breaking Abstract #4)

    Google Scholar 

  • Mishima Y, Paiva B, Shi J et al (2017) The Mutational landscape of circulating tumor cells in multiple myeloma. Cell Rep 19(1):218–224

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Moreau P, San-Miguel J, Sonneveld P et al (2017) Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl 4):iv52–iv61

    Article  CAS  PubMed  Google Scholar 

  • Moreau P, Mateos M-V, Berenson JR et al (2018) Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol 19(7):953–964

    Article  CAS  PubMed  Google Scholar 

  • Moreau P, Attal M, Hulin C et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394:29–38

    Article  CAS  PubMed  Google Scholar 

  • Munshi NC, Avet-Loiseau H, Rawstron AC et al (2017) Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma. JAMA Oncol 3(1):28

    Article  PubMed  PubMed Central  Google Scholar 

  • Neri P, Bahlis NJ, Lonial S (2016) New strategies in multiple myeloma: immunotherapy as a novel approach to treat patients with multiple myeloma. Clin Cancer Res 22(24):5959–5965

    Article  CAS  PubMed  Google Scholar 

  • Palumbo A, Rajkumar SV, San Miguel JF et al (2014) International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 32(6):587–600

    Article  PubMed  PubMed Central  Google Scholar 

  • Palumbo A, Avet-Loiseau H, Oliva S et al (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863–2869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Papatzimas JW, Gorobets E, Maity R et al (2019) From inhibition to degradation: targeting the antiapoptotic protein myeloid cell leukemia 1 (MCL1). J Med Chem 62:5522–5540

    Article  CAS  PubMed  Google Scholar 

  • Perrot A, Lauwers-Cances V, Corre J et al (2018) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132(23):2456–2464

    Article  CAS  PubMed  Google Scholar 

  • Perrot A, Lauwers-Cances V, Tournay E et al (2019) Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol 37(19):1657–1665

    Article  PubMed  Google Scholar 

  • Radamaker L, Lin YH, Annamalai K et al (2019) Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. Nat Commun 10:1103

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Raje N, Berdeja J, Lin Y et al (2019) Anti-BCMA CAR T cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 380:1726–1737

    Article  PubMed  Google Scholar 

  • Rasche L, Angtuaco E, McDonald JE et al (2017a) Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma. Blood 130(1):30–34

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rasche L, Chavan SS, Stephens OW et al (2017b) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8(1):268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rasche L, Angtuaco EJ, Alpe TL et al (2018) The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 132(1):59–66

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rawstron AC, Gregory WM, de Tute RM et al (2015) Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood 125(12):1932–1935

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Richardson PG, Oriol A, Beksac M et al (2019) Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 20(6):781–794

    Article  CAS  PubMed  Google Scholar 

  • Rosinol L, Oriol A, Rios R et al (2017) Bortezomib, lenalidomide and dexamethasone (VRD-GEM) as induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a prospective phase III pethema/GEM trial. Blood 130(Suppl 1):2017

    Google Scholar 

  • Salwender H, Bertsch U, Weisel K et al (2019) Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer 18:504

    Article  CAS  Google Scholar 

  • Sanoja-Flores L, Flores-Montero J, Garcés JJ et al (2018) Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 8(12):117

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sobh M, Michallet M, Gahrton G et al (2016) Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years: a study by the EBMT Chronic Malignancies Working Party. Leukemia 30(10):2047–2054

    Article  CAS  PubMed  Google Scholar 

  • Sonneveld P, Avet-Loiseau H, Lonial S et al (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood 127(24):2955–2962

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Spencer A, Lentzsch S, Weisel K et al (2018) Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica 103(12):2079–2087

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stadtmauer EA, Pasquini MC, Blackwell B et al (2019) Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol 37(7):589–597

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Susanibar Adaniya SP, Cohen AD, Garfall AL (2019) Chimeric antigen receptor T cell immunotherapy for multiple myeloma: a review of current data and potential clinical applications. Am J Hematol 94(S1):S28–S33

    Article  CAS  PubMed  Google Scholar 

  • Thakurta A, Ortiz M, Blecua P et al (2019) High sub-clonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood. https://doi.org/10.1182/blood-2018-10-880831

    Article  PubMed  PubMed Central  Google Scholar 

  • van de Donk NWCJ, Richardson PG, Malavasi F (2017) CD38 antibodies in multiple myeloma: back to the future. Blood. https://doi.org/10.1182/blood-2017-06-740944

    Article  PubMed  Google Scholar 

  • Vaxman I, Sidiqi MH, Gertz M (2018) Venetoclax for the treatment of multiple myeloma. Expert Rev Hematol 11(12):915–920

    Article  CAS  PubMed  Google Scholar 

  • Weisel KC, Scheid C, Zago M et al (2019) Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE multiple myeloma trial. Blood Cancer J 9(4):45

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhao W-H, Liu J, Wang B-Y et al (2018) Updated analysis of a phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B Cell maturation antigen, in patients with relapsed/refractory multiple myeloma. Blood 132(Suppl 1):955

    Article  Google Scholar 

Download references

Acknowledgements

We thank all speakers and participants for their attendance and valuable input at the workshop. Moreover, we thank Annette Hluzek and Andrea Illgner for assistance with organization of the workshop and all sponsors and exhibitors for their support: Abbvie, Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb, Celgene, Chugai, Janssen-Cilag, Molecular Partners, Sanofi-Aventis, Sebia, Takeda and The Binding Site.

Author information

Authors and Affiliations

  1. Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

    M. A. Baertsch, R. Lutz, M. S. Raab, N. Weinhold & H. Goldschmidt

  2. Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, Heidelberg, Germany

    M. S. Raab

  3. National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany

    H. Goldschmidt

Authors
  1. M. A. Baertsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Lutz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. S. Raab
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Weinhold
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. A. Baertsch.

Ethics declarations

Conflict of interest

MAB: Takeda: Consultancy; Novartis: Consultancy, Research Funding; Celgene, Amgen, Janssen: Travel grants. RL: Janssen: Travel grants. MSR: Celgene: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding. NW: No conflict. HG: Amgen: Consultancy, Research Funding; Novartis: Honoraria, Research Funding; ArtTempi: Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Research Funding; Mundipharma: Research Funding; Takeda: Consultancy, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Adaptive Biotechnology: Consultancy; Chugai: Honoraria, Research Funding.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baertsch, M.A., Lutz, R., Raab, M.S. et al. Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow. J Cancer Res Clin Oncol 145, 2445–2455 (2019). https://doi.org/10.1007/s00432-019-02998-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-019-02998-w

Keywords

Search

Navigation